SummaryInteractions between kinases and small molecule inhibitors can be activation state dependent. A detailed understanding of inhibitor binding therefore requires characterizing interactions across multiple activation states. We have systematically explored the effects of ABL1 activation loop phosphorylation and PDGFR family autoinhibitory juxtamembrane domain docking on inhibitor binding affinity. For a diverse compound set, the affinity patterns correctly classify inhibitors as having type I or type II binding modes, and we show that juxtamembrane domain docking can have dramatic negative effects on inhibitor affinity. The results have allowed us to associate ligand-induced conformational changes observed in cocrystal structures with s...
*S Supporting Information ABSTRACT: The ATP site of kinases displays remarkable conformational flexi...
Protein kinases are major drug targets, but the development of highly-selective inhibitors has been ...
Structure-based drug design is commonly used to guide the development of potent and specific enzyme ...
SummaryInteractions between kinases and small molecule inhibitors can be activation state dependent....
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of funda-mental ...
Protein kinases are key components in cellular signalling pathways as they carry out the phosphoryla...
While selective inhibition is one of the key assets for a small molecule drug, many diseases can onl...
The aberrant activation of protein kinases is associated with many human diseases, most notably canc...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Identifying selective kinase inhibitors remains a major challenge. The design of bivalent inhibitors...
We have used a chemically diverse panel of kinase inhibitors to assess the chemical similarity of th...
The aberrant activation of protein kinases is associated with many human diseases, most notably canc...
*S Supporting Information ABSTRACT: The ATP site of kinases displays remarkable conformational flexi...
Protein kinases are major drug targets, but the development of highly-selective inhibitors has been ...
Structure-based drug design is commonly used to guide the development of potent and specific enzyme ...
SummaryInteractions between kinases and small molecule inhibitors can be activation state dependent....
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of funda-mental ...
Protein kinases are key components in cellular signalling pathways as they carry out the phosphoryla...
While selective inhibition is one of the key assets for a small molecule drug, many diseases can onl...
The aberrant activation of protein kinases is associated with many human diseases, most notably canc...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Identifying selective kinase inhibitors remains a major challenge. The design of bivalent inhibitors...
We have used a chemically diverse panel of kinase inhibitors to assess the chemical similarity of th...
The aberrant activation of protein kinases is associated with many human diseases, most notably canc...
*S Supporting Information ABSTRACT: The ATP site of kinases displays remarkable conformational flexi...
Protein kinases are major drug targets, but the development of highly-selective inhibitors has been ...
Structure-based drug design is commonly used to guide the development of potent and specific enzyme ...